Drug-induced autoimmunity

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 4, 2003, Pages 249-253

  Pichler, Werner J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Autoimmunity; Cross reactivity; Drug hypersensitivity; Drug induced autoimmunity

Indexed keywords

ANTIGEN; AUTOANTIGEN; CELL ADHESION MOLECULE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PHOSPHOTRANSFERASE;

ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CROSS REACTION; DRUG HYPERSENSITIVITY; DRUG INDUCED AUTOIMMUNITY; DRUG MECHANISM; ENZYME INHIBITION; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THYMUS;

ANTIGEN-PRESENTING CELLS; AUTOIMMUNITY; CROSS REACTIONS; DRUG HYPERSENSITIVITY; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES;

EID: 0042009750     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200308000-00003     Document Type: Review

References (34)

1. Adams LE, Hess EV. Drug-related lupus. Drug Safety 1991; 6:431-449.
2. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol 1999; 11:357-363.
3. Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19:133-141.
4. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483-507.
5. Weltzien HU, Moulin C, Martin S, et al. T-cell immune response to haptens: structural models for allergic and autoimmune reactions. Toxicology 1996; 107:141-151.
6. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors (the p-i-concept). Curr Opin Allergy Clin Immunol 2002; 2:301-305. A summary of the findings leading to the novel concept that drugs might stimulate T cells directly.
7. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344:655-663.
8. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance: a murine model of drug-induced lupus. J Clin Invest 1997; 99:1888-1896.
9. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 2000; 6:298-305.
10. Rubin RL, Kretz-Rommel A. A nondeletional mechanism for central T cell tolerance. Crit Rev Immunol 2001; 21:29-40.
11. Datta SK. Positive selection for autoimmunity. Nat Med 2000; 6:259-261.
12. Medzhitov R, Janeway Jr C. Innate immunity. N Engl J Med 2000; 343:338-344.
13. + T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002; 196:1335-1346.
14. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002; 110:693-702.
15. Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus II: T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866-2871.
16. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48:746-756. This study unravels the underlying mechanism of the SLE-inducing properties of hydralazine and procainamide, as these drugs interfere with the ERK pathway and thus inhibit methyltransferase activity. Drug-induced lupus may thus have a similar signalling defect as idiopathic lupus.
17. Richardson B, Strahler JR, Pivirotto TS, et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 1992; 35:647-662.
18. Gleichmann E, Griem P, Panthel K, Kalbacher H. Alternation of a model antigen by Au (111) leads to T cell sensitization to cryptic peptides. Eur J Immunol 1996; 26:279-287.
19. Padovan E, Bauer T, Tongio MM, et al. Penicilloyl peptides are recognized as T-cell antigenic determinants in penicillin allergy. Eur J Immunol 1997; 27:1303-1307.
20. Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazol to human T-cell clones. J Clin Invest 1997; 100:136-141.
21. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human αβT lymphocytes. J Clin Invest 1998; 102:1591-1598.
22. Zanni MP, Mauri-Hellweg D, Brander Ch, et al. Characterization of lidocaine specific T cells. J Immunol 1997; 158:1139-1148.
23. Naisbitt DJ, Britschgi M, Wong G, et al. Characterization of skin homing lamotrigine-specific T-cells from hypersensitive patients. J Allergy Clin Immunol 2003; 111:1393-1403. A very detailed analysis of the lamotrigine specific T cell immune response in patients with lamotrigine hypersensitivity.
24. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T-cell clones. Mol Pharm 2003; 63:732-741. A detailed analysis of T-cell clones from patients with anticonvulsant drug hypersensitivity syndrome showed low IL-5 but high IFNγ production, which differs from the T-cell clones isolated from patients with exclusive cutaneous symptoms.
25. Sieben S, Kawabuko Y, Al Masaoudi T, et al. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J Allergy Clin Immunol 2002; 109:1005-1011. Paraphenylendiamine is a classical contact sensitizer. It was hitherto thought that an autoxidation product (Bandrowski's base) induces the reaction. The study suggests two distinct pathways of antigen presentation exist to activate the immune response to paraphenylendiamine, namely a direct recognition of paraphenylendiamine by T cells through a processing-independent pathway and a processing and possibly metabolism-dependent pathway leading to recognition of Bandrowski's base.
26. Schnyder B, Burkhart C, Schnyder-Frutig K, et al. Recognition of sulfamethoxazol and its reactive metabolites by drug specific T-cells from allergic individuals. J Immunol 2000; 164:6647-6654.
27. Martin S, Weltzien HU. T cell recognition of haptens, a molecular view. Int Arch Allergy Immunol 1994; 104:10-16.
28. Martin S, Ortmann B, Pflugfelder U, et al. Role of hapten-anchoring peptides in defining hapten-epitopes for MHC-restricted cytotoxic T cells: cross-reactive TNP-determinants on different peptides. J Immunol 1992; 149:2569-2575.
29. von Greyerz S, Burkhart C, Pichler WJ. Molecular basis of drug recognition by specific T-cell receptors. Int Arch Allergy Immunol 1999; 119:173-180.
30. von Greyerz S, Bültemann G, Schnyder K, et al. Degeneracy and additional alloreactivity of drug-specific human αβ+ T-cell clones. Int Immunol 2001; 7:877-885.
31. Zanni MP, von Greyerz S, Schnyder B, et al. HLA-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T-cell clones. Int Immunol 1998; 10:507-515.
32. Britschgi M, Steiner U, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 11:1433-1441.
33. Schnyder B, Helbling A, Kappeler A, Pichler WJ. Drug induced papulovesicular exanthema. Allergy 1998; 53:817-818.
34. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA. B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732. This is the most convincing demonstration of an HLA association with a certain form of drug hypersensitivity reaction.